Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyChallenges in the diagnosis and management of acromegaly: a focus on comorbidities.Growth hormone and the heart.Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Management of acromegaly in Latin America: expert panel recommendationsClinical Use of Cinacalcet in MEN1 HyperparathyroidismCurrent management of acromegaly.Evolving therapeutic strategies for acromegaly.Primary medical therapy for acromegaly.Modern treatment of acromegaly.Medical therapy of acromegalyCurrent pharmacotherapy for acromegaly: a review.Treatment strategies for acromegaly.Growth hormone and its disordersPatient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.Newer options in the management of acromegaly.From somatostatin to octreotide LAR: evolution of a somatostatin analogueNanomedicines in the treatment of acromegaly: focus on pegvisomant.Somatostatin agonists for treatment of acromegaly.Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Self-limited acute hepatotoxicity caused by pegvisomant.δ-opioid receptor and somatostatin receptor-4 heterodimerization: possible implications in modulation of pain associated signaling.Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.Octreotide LAR: safety and tolerability issues.Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.Medical therapy in acromegaly.Octreotide long-acting repeatable for acromegaly.Management options for persistent postoperative acromegaly.Octreotide for acromegaly treatment: a reappraisal.Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly.Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.Dose optimization of somatostatin analogues for acromegaly patients.Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.Men with acromegaly need higher doses of octreotide than women.Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
P2860
Q26777682-60E2B6E9-5D3F-499D-A16F-88D8F83C8FCEQ30249746-970F7343-9E2E-422A-9FE3-8380F5CB05EFQ32026861-7BC4F462-B03E-4584-B277-BFA336F84478Q33422743-891D3535-DF10-4CB5-8C81-870D3B427F3FQ33772673-A3EFC739-EEE3-45C5-893A-F4A6A2CE0D53Q33794388-E09DE93C-CDD6-4692-B825-01D8FF3D065BQ33879558-6B9787CA-5A6F-43B4-B1E8-348973BD97EAQ34182034-4DC6A00A-AA08-4BB7-A474-4A1DC5F66505Q34297663-10C07CD6-68DE-44EC-89B2-B0BDD54AC450Q35086868-A59A2C9A-2E90-4EEE-A900-3789BDBE68C8Q35125987-CBC1986D-82FF-4E88-A137-1FD36CE89233Q35895856-F1954073-F69D-49D8-96EC-EEC0AC3FA8E8Q36301564-F6D14846-438C-4032-834A-F027CB2C09DBQ36302865-34D42F98-A91F-48C0-BAAB-D82CBEA2A7BCQ36362200-CE8077AD-0720-4121-AC59-6A00F0DE13F9Q36489627-C37994CB-4DCA-4729-B3DC-CCB91C6797B1Q36509265-C13BAB0C-A110-4E04-BA64-0CFEEFF7B8A2Q36919554-08A7AD69-D752-4035-BF86-593EDFF9F4E7Q36920317-5D926E5E-B2AA-4C82-925D-9E2106A2D9D4Q37055643-46EA22D4-5C53-453E-9521-AFF773750FECQ37292997-C3E8B1C4-E8ED-4382-B5B1-3D265FCC522FQ37321948-D1D47174-1DBA-4E79-A5F9-2491AA78E023Q37407902-356D9092-82A3-4B7A-9096-E5D6ED9D7671Q37453223-B59DDDAB-C257-4442-987E-4C1264C675CEQ37617510-CF23ED9D-ACF4-4302-ADF4-C4B1F5B1307AQ37649647-E683D5E9-8C43-43EF-A81F-FC47F60DC4A1Q37663006-D7D6ACB7-EC83-47AF-B6A4-1CF4458BEAE1Q37859250-A0ACDEB5-6F6D-4D7E-AEEE-5239460102B5Q37990556-2E218D1B-3136-4023-AA6E-82F10994F809Q38049832-6DFE4F96-AE93-4DF8-AF6A-01144E2CC498Q38152458-3B249427-C654-4F39-8770-49D6F39A6868Q42378746-9984B3F8-5D9A-4243-A076-B743AA0C3777Q42450481-9C0BD3AA-91ED-4F76-A24C-44D7E9D97D82Q42482027-AB047B71-054A-4A07-90AE-4FE35497CA10Q42483024-81748E96-4823-4F3E-9E5A-8BB186E24F87Q43116265-892D9843-3B3D-478A-B771-C928737CC18FQ43222345-339F03A3-DD66-44C5-A940-06C4DA60B16DQ43889400-1B1D81F6-4C93-4625-A4D1-2AD6E0F96020Q44311518-6F511177-D29C-4603-BC01-9C139A8E0D48Q44331741-57DA5D13-7FEC-4E2B-982F-45BF058B99DE
P2860
Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Results of a European multicen ...... tients. Sandostatin LAR Group.
@ast
Results of a European multicen ...... tients. Sandostatin LAR Group.
@en
type
label
Results of a European multicen ...... tients. Sandostatin LAR Group.
@ast
Results of a European multicen ...... tients. Sandostatin LAR Group.
@en
prefLabel
Results of a European multicen ...... tients. Sandostatin LAR Group.
@ast
Results of a European multicen ...... tients. Sandostatin LAR Group.
@en
P356
P1433
P1476
Results of a European multicen ...... tients. Sandostatin LAR Group.
@en
P2093
Atkinson AB
Lancranjan I
P2888
P304
P356
10.1023/A:1009980404404
P577
1999-01-01T00:00:00Z
P6179
1037110866